KURA
HEALTHCAREKura Oncology Inc
$9.56+0.27 (+2.91%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KURA Today?
No stock-specific AI insight has been generated for KURA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.45$12.49
$9.56
Fundamentals
Market Cap$849M
P/E Ratio—
EPS$-3.18
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding88.8M
KURA News
20 articles- Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceYahoo Finance·May 6, 2026
- Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should KnowYahoo Finance·May 5, 2026
- Kura Oncology to Report First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 ReassessmentYahoo Finance·May 4, 2026
- Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 30, 2026
- Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLGlobeNewswire Inc.·Apr 24, 2026
- KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study DataYahoo Finance·Apr 20, 2026
- Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?Yahoo Finance·Apr 20, 2026
- How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst TargetsYahoo Finance·Apr 19, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Apr 17, 2026
- Sector Update: Health Care Stocks Higher Friday AfternoonYahoo Finance·Apr 17, 2026
- Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire Inc.·Apr 17, 2026
- Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026Yahoo Finance·Apr 9, 2026
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Implied Volatility Surging for Kura Oncology Stock OptionsYahoo Finance·Mar 12, 2026
- How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street TargetsYahoo Finance·Mar 8, 2026
- Kura Oncology Q4 Earnings Call HighlightsMarketbeat·Mar 6, 2026
- Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ...Yahoo Finance·Mar 5, 2026
- Kura Oncology, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 5, 2026
All 20 articles loaded
Price Data
Open$9.35
Previous Close$9.29
Day High$9.61
Day Low$9.27
52 Week High$12.49
52 Week Low$5.45
52-Week Range
$5.45$12.49
$9.56
Fundamentals
Market Cap$849M
P/E Ratio—
EPS$-3.18
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding88.8M
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—